MYGN Form 3 Filing: CFO Benjamin R. Wheeler Discloses 35,210 Shares

Rhea-AI Filing Summary

Benjamin R. Wheeler, identified as Chief Financial Officer and director, reported beneficial ownership of 35,210 shares of Myriad Genetics, Inc. (MYGN) in an initial Form 3 covering an event dated 08/16/2025. The filing lists Wheeler's address in Salt Lake City, UT, and includes an Exhibit 24 power of attorney. The Form 3 was signed on behalf of Wheeler by Justin Hunter on 08/19/2025.

Positive

• Insider disclosure completed, increasing transparency about executive ownership
• Direct ownership clearly reported: 35,210 common shares
• Exhibit 24 power of attorney included, indicating authorized filing procedure

Negative

• None.

Insights

Financial Analyst

TL;DR Disclosure of 35,210 shares by the CFO is routine insider reporting and has limited direct market impact.

The filing is a standard initial beneficial ownership report under Section 16 showing direct ownership of 35,210 common shares by the company's CFO and director. There are no derivative holdings, no amendments, and no transaction details such as acquisition price or grant dates. For investors, this is a compliance disclosure that increases transparency but provides no new operational or financial information about Myriad Genetics.

Corporate Governance Expert

TL;DR This Form 3 documents an officer/director's holdings and includes a power of attorney; it is a routine governance disclosure.

The report confirms Benjamin R. Wheeler's status as both an officer (CFO) and director and lists his direct ownership of common stock. The inclusion of Exhibit 24 indicates delegation of filing authority. There are no red flags such as undisclosed indirect holdings or derivative instruments. The disclosure meets Section 16 reporting requirements but does not by itself signal governance changes or related-party transactions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wheeler Benjamin Richard

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 35,210 shares (Direct)

Footnotes (1)

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wheeler Benjamin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/16/2025

3. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	35,210	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	By: Justin Hunter For: Benjamin R. Wheeler	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benjamin R. Wheeler disclose on the Form 3 for MYGN?

The Form 3 reports direct ownership of 35,210 common shares of Myriad Genetics and identifies Wheeler as Chief Financial Officer and director.

When is the event date and filing date on the Form 3 for MYGN?

The event requiring the statement is dated 08/16/2025 and the Form 3 was signed on behalf of Wheeler on 08/19/2025.

Does the Form 3 show any derivative securities for Benjamin R. Wheeler?

No. The filing lists only non-derivative common stock holdings and shows no derivative securities.

What is Exhibit 24 in this filing?

Exhibit 24 is a power of attorney authorizing an agent to sign and file the Form 3 on behalf of the reporting person.

Does this Form 3 indicate any sales or purchases of MYGN shares?

No transactional details such as purchases or sales, prices, or grant dates are included; the form reports current beneficial ownership only.